ID16512A - Superantigen yang dimodifikasi/semu dan penggunaannya - Google Patents
Superantigen yang dimodifikasi/semu dan penggunaannyaInfo
- Publication number
- ID16512A ID16512A IDP971022A ID971022A ID16512A ID 16512 A ID16512 A ID 16512A ID P971022 A IDP971022 A ID P971022A ID 971022 A ID971022 A ID 971022A ID 16512 A ID16512 A ID 16512A
- Authority
- ID
- Indonesia
- Prior art keywords
- modified
- cells
- superantigen
- subset
- replaced
- Prior art date
Links
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 231100000617 superantigen Toxicity 0.000 abstract 3
- 230000004913 activation Effects 0.000 abstract 2
- 235000018417 cysteine Nutrition 0.000 abstract 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 150000001945 cysteines Chemical class 0.000 abstract 1
- 229960003067 cystine Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9601245A SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Chimeric superantigens and their use |
| US08/695,692 US6514498B1 (en) | 1996-03-19 | 1996-08-12 | Modified/chimeric superantigens and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ID16512A true ID16512A (id) | 1997-10-02 |
Family
ID=26662565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IDP971022A ID16512A (id) | 1996-03-29 | 1997-03-27 | Superantigen yang dimodifikasi/semu dan penggunaannya |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7226595B2 (de) |
| EP (1) | EP0835266B1 (de) |
| JP (1) | JP4114951B2 (de) |
| AT (1) | ATE294818T1 (de) |
| AU (1) | AU707827B2 (de) |
| BR (1) | BR9702179A (de) |
| CA (1) | CA2222757C (de) |
| CZ (1) | CZ294475B6 (de) |
| DE (1) | DE69733179T2 (de) |
| ES (1) | ES2242222T3 (de) |
| HU (1) | HU228185B1 (de) |
| ID (1) | ID16512A (de) |
| IL (1) | IL122211A (de) |
| MX (1) | MX9709265A (de) |
| NO (1) | NO321984B1 (de) |
| NZ (1) | NZ329145A (de) |
| PL (1) | PL189696B1 (de) |
| PT (1) | PT835266E (de) |
| TW (1) | TW517061B (de) |
| WO (1) | WO1997036932A1 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9402430L (sv) * | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
| TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| US7276488B2 (en) | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
| EP1012259B1 (de) | 1997-06-04 | 2009-09-30 | Oxford Biomedica (UK) Limited | Tumor gezielter Vektor |
| US6713284B2 (en) | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
| US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
| EA002688B1 (ru) * | 1997-07-21 | 2002-08-29 | Фармациа Энд Апджон Аб | Способы инактивации клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, используемые для получения этих агентов |
| US6872394B1 (en) | 1997-12-02 | 2005-03-29 | Idaho Research Foundation, Inc. | Non-toxic immune stimulating enterotoxin compositions |
| WO1999027889A2 (en) * | 1997-12-02 | 1999-06-10 | Idaho Research Foundation, Inc. | Non-toxic immune stimulating enterotoxin compositions |
| AU762813B2 (en) * | 1998-08-13 | 2003-07-03 | Walter Reed Army Institute Of Research | Bacterial superantigen vaccines |
| US7491402B2 (en) * | 1998-12-24 | 2009-02-17 | Auckland Uniservices Limited | Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof |
| EP1242456B1 (de) | 1999-11-18 | 2008-10-15 | Oxford Biomedica (UK) Limited | Scfv antikörper gegen krankheiten-assoziierte moleküle |
| US20030124142A1 (en) * | 2000-12-04 | 2003-07-03 | Fraser John David | Immunomodulatory constructs and their uses |
| SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| WO2003095481A1 (en) * | 2002-05-09 | 2003-11-20 | Auckland Uniservices Limited | Streptococcal superantigens spe-l and spe-m |
| NZ519371A (en) * | 2002-06-04 | 2004-11-26 | Auckland Uniservices Ltd | Immunomodulatory constructs and their uses |
| US8025873B2 (en) | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| SE0402025D0 (sv) * | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| JP2008520227A (ja) * | 2004-11-18 | 2008-06-19 | メディジーン リミテッド | 可溶性二官能性タンパク質 |
| WO2006105168A2 (en) * | 2005-03-29 | 2006-10-05 | Regents Of The University Of Minnesota | Enhancing immune responses with bacterial exotoxins |
| US20070178113A1 (en) * | 2005-11-22 | 2007-08-02 | Backstrom B T | Superantigen conjugate |
| CA2755640C (en) * | 2009-03-20 | 2018-05-22 | Genentech, Inc. | Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B1 (de) | 2010-10-01 | 2020-12-30 | ModernaTX, Inc. | Manipulierte nukleinsäuren und verfahren zur verwendung davon |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012318752B2 (en) | 2011-10-03 | 2017-08-31 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2833923A4 (de) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | Modifizierte polynukleotide zur herstellung von proteinen |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3010535B1 (de) * | 2013-06-19 | 2019-08-14 | Integrated Biotherapeutics, Inc. | Aus phenollöslichem modulin gewonnene toxoidpeptide, delta-toxin, superantigene und fusionen davon |
| BR112016004355A2 (pt) * | 2013-08-30 | 2017-10-17 | Aprilbio Co Ltd | constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| WO2017122098A2 (en) | 2016-01-10 | 2017-07-20 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy. |
| CN110996993B (zh) | 2017-07-27 | 2024-05-31 | Ab疫苗公司 | 包含源自超抗原类毒素的融合肽的免疫原性组合物 |
| JPWO2020162203A1 (de) * | 2019-02-08 | 2020-08-13 | ||
| EA202193121A1 (ru) | 2019-05-15 | 2022-02-21 | Неоткс Терапьютикс Лтд. | Лечение рака |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| AU2021357520A1 (en) | 2020-03-05 | 2022-09-29 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
| WO2024077066A1 (en) * | 2022-10-05 | 2024-04-11 | Musc Foundation For Research Development | Superantigen vaccine conjugate for the treatment of cancer |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3627644A (en) * | 1968-03-01 | 1971-12-14 | Hajime Okamoto | Process for the cultivation of hemolytic streptococci |
| US3903262A (en) * | 1972-03-13 | 1975-09-02 | Cutter Lab | Pharmaceutical compositions comprising intravenously injectable modified serum globulin, its production and use |
| US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| GB1587244A (en) | 1977-07-01 | 1981-04-01 | Memm Spa | Streptococcal antigen pharmaceutical compositions containing it and its use in medical diagnosis and treatment |
| US4268434A (en) * | 1979-01-09 | 1981-05-19 | Higerd Thomas B | Immunosuppressive extracellular product from oral bacteria |
| US5091091A (en) * | 1981-11-06 | 1992-02-25 | Terman David S | Protein A perfusion and post perfusion drug infusion |
| US4699783A (en) * | 1983-03-11 | 1987-10-13 | Terman David S | Products and methods for treatment of cancer |
| US4681870A (en) * | 1985-01-11 | 1987-07-21 | Imre Corporation | Protein A-silica immunoadsorbent and process for its production |
| FR2589267B1 (fr) | 1985-10-25 | 1991-05-31 | Bertin & Cie | Procede de traitement d'images, notamment dans une installation de tri postal |
| US4980160A (en) | 1986-10-16 | 1990-12-25 | Biogen, Inc. | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases |
| EP0336562B1 (de) | 1988-03-04 | 1995-06-14 | Cancer Research Campaign Technology Ltd. | Antigene |
| DE68907388T2 (de) | 1988-07-22 | 1994-01-05 | Imre Corp | Gereinigte Protein A-Zusammensetzungen und Verfahren zu ihrer Herstellung. |
| DE3921211C1 (de) | 1989-06-28 | 1990-11-29 | Idt Ag Fuer In Vivo Diagnostik Und Therapie, Zuerich, Ch | |
| US6042837A (en) * | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
| SE8903100D0 (sv) | 1989-09-20 | 1989-09-20 | Pharmacia Ab | New pharmaceutical agent |
| US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| US5728388A (en) * | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| DE69133485T2 (de) | 1990-01-17 | 2006-06-22 | Terman, David S., Pebble Beach | Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie |
| SE465328B (sv) | 1990-02-19 | 1991-08-26 | Duotech Innovation Ab | Kompensationsventil |
| KR100189024B1 (ko) | 1990-07-20 | 1999-06-01 | 존 해던쉬트롬 | 항체 및 초항원을 포함하는 가용성 항체 결합체 및 그 제조방법 |
| US6197299B1 (en) * | 1990-07-20 | 2001-03-06 | Pharmacia & Upjohn Ab | Antibody conjugates |
| US5858363A (en) * | 1990-07-20 | 1999-01-12 | Pharmacia & Upjohn Ab | Target specific antibody-superantigen conjugates and their preparation |
| WO1993024136A1 (en) | 1991-01-17 | 1993-12-09 | Terman David S | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| US6090914A (en) * | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
| EP0626805A4 (en) | 1992-01-28 | 1995-12-06 | Nat Jewish Ct Immun & Respirat | Protective effects of mutated superantigens. |
| US5545716A (en) * | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
| US5519114A (en) * | 1993-10-29 | 1996-05-21 | University Of Florida Research Foundation, Inc. | Retroviral superantigens, superantigen peptides, and methods of use |
| SE9402430L (sv) * | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
| US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| AU723116B2 (en) * | 1995-06-07 | 2000-08-17 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin A and methods of use |
| SE9601245D0 (sv) * | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
| TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| WO1997036614A1 (en) * | 1996-03-29 | 1997-10-09 | Terman David S | Polymerized staphylococcal protein a for treatment of diseases |
| US6774218B2 (en) * | 1996-12-06 | 2004-08-10 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin C and methods of use |
| EP0946730B1 (de) * | 1996-12-06 | 2006-03-08 | Regents Of The University Of Minnesota | Mutanten von streptococcaltoxin c und verfahren zu deren anwendung |
| WO1998024911A2 (en) * | 1996-12-06 | 1998-06-11 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin a and methods of use |
| WO1998026747A2 (en) * | 1996-12-17 | 1998-06-25 | Terman David S | Superantigen based methods and compositions for treatment of diseases |
| IL119938A (en) * | 1996-12-30 | 2005-08-31 | Yissum Res Dev Co | Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells |
| US6713284B2 (en) * | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
| US7087235B2 (en) * | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
| WO1999036433A2 (en) * | 1998-01-14 | 1999-07-22 | Morphogenesis, Inc. | Materials and methods for treating oncological disease |
| EP1097212B1 (de) * | 1998-07-10 | 2008-12-24 | U.S. Medical Research Institute of Infectious Diseases | Anthrax-impfstoff |
| US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US20030157113A1 (en) * | 1999-12-28 | 2003-08-21 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US20010046501A1 (en) * | 2000-03-14 | 2001-11-29 | Johnson Howard M. | Superantigen enhancement of specific immune responses |
| JP4283430B2 (ja) * | 2000-09-26 | 2009-06-24 | 株式会社カネカ | エンテロトキシンの吸着材、吸着除去方法および吸着器 |
| US20030124142A1 (en) * | 2000-12-04 | 2003-07-03 | Fraser John David | Immunomodulatory constructs and their uses |
| CN1369550A (zh) * | 2001-02-16 | 2002-09-18 | 沈阳协合集团有限公司 | 一种金黄色葡萄球菌的培养物及其制备方法 |
| SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
-
1997
- 1997-03-24 TW TW086103689A patent/TW517061B/zh not_active IP Right Cessation
- 1997-03-26 PT PT97916693T patent/PT835266E/pt unknown
- 1997-03-26 EP EP97916693A patent/EP0835266B1/de not_active Expired - Lifetime
- 1997-03-26 DE DE69733179T patent/DE69733179T2/de not_active Expired - Lifetime
- 1997-03-26 AU AU25251/97A patent/AU707827B2/en not_active Ceased
- 1997-03-26 PL PL97323626A patent/PL189696B1/pl not_active IP Right Cessation
- 1997-03-26 BR BR9702179A patent/BR9702179A/pt not_active Application Discontinuation
- 1997-03-26 IL IL122211A patent/IL122211A/en not_active IP Right Cessation
- 1997-03-26 ES ES97916693T patent/ES2242222T3/es not_active Expired - Lifetime
- 1997-03-26 CA CA2222757A patent/CA2222757C/en not_active Expired - Fee Related
- 1997-03-26 HU HU9903444A patent/HU228185B1/hu not_active IP Right Cessation
- 1997-03-26 CZ CZ19973712A patent/CZ294475B6/cs unknown
- 1997-03-26 MX MX9709265A patent/MX9709265A/es not_active IP Right Cessation
- 1997-03-26 JP JP53519897A patent/JP4114951B2/ja not_active Expired - Fee Related
- 1997-03-26 WO PCT/SE1997/000537 patent/WO1997036932A1/en active IP Right Grant
- 1997-03-26 NZ NZ329145A patent/NZ329145A/en not_active IP Right Cessation
- 1997-03-26 AT AT97916693T patent/ATE294818T1/de active
- 1997-03-27 ID IDP971022A patent/ID16512A/id unknown
- 1997-11-26 NO NO19975435A patent/NO321984B1/no not_active IP Right Cessation
-
2002
- 2002-10-30 US US10/283,838 patent/US7226595B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002502363A (ja) | 2002-01-22 |
| CZ294475B6 (cs) | 2005-01-12 |
| DE69733179T2 (de) | 2005-10-06 |
| WO1997036932A1 (en) | 1997-10-09 |
| CZ371297A3 (cs) | 1998-05-13 |
| ES2242222T3 (es) | 2005-11-01 |
| HUP9903444A3 (en) | 2003-08-28 |
| TW517061B (en) | 2003-01-11 |
| ATE294818T1 (de) | 2005-05-15 |
| HU228185B1 (en) | 2013-01-28 |
| NO321984B1 (no) | 2006-07-31 |
| IL122211A0 (en) | 1998-04-05 |
| BR9702179A (pt) | 1999-03-16 |
| EP0835266A1 (de) | 1998-04-15 |
| PT835266E (pt) | 2005-07-29 |
| DE69733179D1 (de) | 2005-06-09 |
| HUP9903444A2 (hu) | 2000-02-28 |
| NZ329145A (en) | 2000-06-23 |
| MX9709265A (es) | 1998-03-31 |
| CA2222757A1 (en) | 1997-10-09 |
| CA2222757C (en) | 2011-07-26 |
| PL189696B1 (pl) | 2005-09-30 |
| AU2525197A (en) | 1997-10-22 |
| NO975435L (no) | 1998-01-29 |
| US20030092894A1 (en) | 2003-05-15 |
| EP0835266B1 (de) | 2005-05-04 |
| US7226595B2 (en) | 2007-06-05 |
| PL323626A1 (en) | 1998-04-14 |
| JP4114951B2 (ja) | 2008-07-09 |
| IL122211A (en) | 2009-07-20 |
| AU707827B2 (en) | 1999-07-22 |
| NO975435D0 (no) | 1997-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ID16512A (id) | Superantigen yang dimodifikasi/semu dan penggunaannya | |
| Ichikawa et al. | VR1-immunoreactive primary sensory neurons in the rat trigeminal ganglion | |
| Nakashima et al. | The amino acid composition is different between the cytoplasmic and extracellular sides in membrane proteins | |
| TIMPL et al. | Nature of the collagenous protein in a tumor basement membrane | |
| SE9601245D0 (sv) | Chimeric superantigens and their use | |
| DK1218751T3 (da) | Cöliakidiagnose under anvendelse af et gliadinepitop | |
| KR900013979A (ko) | 사람 유두종비루스형 16의 e7 단백질상의 면역원성 영역 | |
| BR9810907A (pt) | Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico | |
| ATE122394T1 (de) | Pankreatische isletzellen-antigene, erhalten durch molekulare klonierung. | |
| FR2660757B1 (fr) | Procede d'identification ou de dosage de proteines et applications. | |
| DE69030937T2 (de) | Mutanten von Interleukin-3 | |
| CA2240409A1 (en) | Mammalian cx3c chemokine genes | |
| KR970706306A (ko) | 펩티드들과 그들을 포함하는 약학적 조성물들 | |
| US20060217302A1 (en) | Paralytic peptide for use in neuromuscular therapy | |
| KR940703920A (ko) | 시그날-펩타이드-유리 스태필로키나제의 발현 | |
| KR940005665A (ko) | 분리된 폴리펩티드, 이를 암호하는 핵산 분자, 상기 폴리펩티드를 포함하는 조성물 및 이를 사용하는 방법 | |
| Yamada et al. | Purification, molecular properties and biosynthesis of a specific protein component induced under compensatory hypertrophy in the rat skeletal muscle | |
| Yonaha et al. | Characterization of three hemorrhagic factors from the venom of Okinawa habu (Trimeresurus flavoviridis) | |
| Brimhall et al. | Amino acid sequence of the hemoglobin of raccoon (Procyon lotor) | |
| Matsumoto et al. | Immunoelectron microscopic localization of dopamine β-hydroxylase and chromogranin A in adrenomedullary chromaffin cells | |
| DE69631624D1 (de) | Antikörper gegen menschliches restrictin | |
| KR880701247A (ko) | T-4 수용체에 대한 결합을 억제하며, 면역원으로서 작용하는 소형 펩티드 | |
| WO2003044159A9 (en) | Zinc finger proteins, polynucleotides encoding same and antibodies thereto | |
| Goodman et al. | Specificity of the action of parathyroid hormone upon mitochondrial metabolism: Cyanogen bromide-derived parathyroid-hormone peptides | |
| Frutiger et al. | Structural variability of rabbit secretory components. Allotype-associated differences in the third, fourth, and fifth domains. |